[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carcinoid-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carcinoid-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,57,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100599635","phase-3-carcinoid-syndrome-efficacy-study-featuring-an-oral-daily-paltusotine-regimen-100599635",false,"NCT07087054","Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors","CAREFNDR","Inclusion Criteria:\n\n* Male or female ≥18 years of age, at the time of Screening.\n* Willing and able to comply with the study procedures as specified in the protocol, including at least 70% compliance with the study diary for the 2-week period.\n* Documented carcinoid syndrome requiring medical therapy. Participants must exhibit symptoms of flushing with or without frequent BMs as follows:\n\n  * For participants who are naïve\u002Fnot currently treated with somatostatin receptors ligands (SRL), they must exhibit an average of \\>1 flushing episode\u002Fday over a period of 14 days\n  * For participants who will wash out from SRL treatment, they must be symptomatically controlled and exhibit an increase in daily average flushing episodes and an average of \\>1 flushing episode\u002Fday over a period of 14 days during the Washout Period.\n* Evaluable documentation of locally advanced or metastatic histopathologically confirmed well-differentiated neuroendocrine tumor(s) \\[NETs\\].\n* No significant disease progression as assessed by the Investigator within the last 6 months before randomization.\n\nExclusion Criteria:\n\n* Diarrhea attributed to any condition(s) other than carcinoid syndrome.\n* Uncontrolled\u002Fsevere diarrhea associated with significant volume contraction, dehydration, or hypotension.\n* Requires second line treatments (eg, telotristat) for control of carcinoid syndrome symptoms in the opinion of the Investigator.\n* Treatment with specific NET therapy \\\u003C4 weeks before Screening (such as everolimus or sunitinib) or hepatic embolization, radiotherapy, peptide receptor radionuclide therapy (PRRT), and\u002For tumor debulking \\\u003C12 weeks before Screening.\n* Major surgery within 8 weeks before Screening.\n* History of another primary malignancy \\\u003C3 years prior to the date of randomization, except for adequately treated basal or squamous cell carcinoma of the skin, cancer of the breast has been completely locally excised and carcinoma in situ of the cervix has also been resected, previously treated malignancy, if all treatment for that malignancy was completed at least 3 years prior to first dose of study treatment, and no current evidence of disease, concurrent malignancy determined to be clinically stable and not requiring treatment.\n* Diabetes mellitus treated with insulin for less than 6 weeks prior to the study entry.\n* Poorly controlled diabetes mellitus defined as having a hemoglobin A1c (HbA1c) ≥8.5%\n* Unable to administer short-acting (SA) octreotide (octreotide acetate injection), or prior nonresponse documented with somatostatin agonists.\n* Clinically significant concomitant disease or indicator of disease that is not a result of the primary disease under study, including but not limited to cardiovascular disease, estimated glomerular filtration rate 2×upper limit of normal \\[ULN\\], and\u002For total bilirubin (TB) \\>1.5×ULN. (Participants with previously diagnosed Gilbert's syndrome not accompanied by other hepatobiliary disorders and associated with TB\n* Alcohol or drug abuse is not permitted at any time during the study\n* Diagnosed with symptomatic cholelithiasis","ALL","18 Years",{"count":20,"type":21},141,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome.",[27,28,29,30,31,32,33,34,35],"Carcinoid Syndrome","Carcinoid","Carcinoid Tumor","Carcinoid Tumor of Ileum","Carcinoid Tumor of Cecum","Carcinoid Tumor of Liver","Carcinoid Tumor of Pancreas","Carcinoid Syndrome Diarrhea","Carcinoid Intestine Tumor",[37,38,39,40,41,42,43],"Neuroendocrine tumor","Paltusotine","CRN00808","Carcinoid syndrome","Lanreotide","Octreotide","Somatostatin agonist","RECRUITING","2026-06-23",{"date":47,"type":48},"2026-06-25","ACTUAL",{"date":50,"type":48},"2025-11-19",{"date":52,"type":21},"2030-01",{"name":54,"class":55},"Crinetics Pharmaceuticals Inc.","INDUSTRY",51,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":91},"100627565","cardionetpol-national-registry-of-carcinoid-heart-disease-100627565","NCT07450287","CardioNETPOL National Registry of Carcinoid Heart Disease","Carcinoid Heart Disease National Registry of Poland","CardioNETPOL","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Confirmed diagnosis of a neuroendocrine tumor consistent with carcinoid heart disease.\n* Echocardiographic evidence of at least moderate valvular disease associated with endocardial fibrosis.\n* Elevated NT-proBNP levels (\\>260 ng\u002FL) consistent with cardiac dysfunction.\n* Availability of relevant clinical, echocardiographic, and laboratory data.\n* For patients who underwent cardiac surgery, histopathological confirmation of carcinoid-related cardiac tissue (if available).\n* Ability to provide informed consent for participation in the registry (or waiver as per local ethics approval for retrospective data).\n\nExclusion Criteria:\n\n* Patients with insufficient clinical or imaging data to confirm carcinoid heart disease.\n* Presence of other primary cardiac conditions causing significant valvular disease unrelated to carcinoid syndrome (e.g., rheumatic heart disease, congenital valve disease)\n* Active participation in interventional clinical trials that would conflict with registry data collection\n* Patients younger than 18 years",{"count":66,"type":21},120,"OBSERVATIONAL","Carcinoid tumors are neuroendocrine tumors (NETs), most commonly originating from the gastrointestinal tract, that may secrete bioactive substances such as serotonin. Persistent exposure to these mediators can lead to carcinoid syndrome and, in up to 50% of patients, carcinoid heart disease (CHD). CHD is characterized by fibrotic degeneration of cardiac valves, predominantly right-sided, resulting in progressive valvular dysfunction and a significant increase in mortality.\n\nThe mechanisms underlying selective cardiac involvement and predictors of disease progression remain incompletely understood. In addition, optimal timing and selection of surgical versus transcatheter valve interventions, particularly in high-risk patients, require further clarification.\n\nThis multicenter, retrospective observational registry aims to identify and characterize patients with carcinoid heart disease and at least moderate valvular involvement. CHD is defined by confirmed neuroendocrine tumor, echocardiographic evidence of ≥ moderate valvular disease with features of fibrosis, elevated NT-proBNP (\\>260 ng\u002FL), and histopathological confirmation when available.\n\nApproximately 100-120 consecutive patients will be enrolled over 12 months. Standardized data collection will include detailed echocardiographic assessment, demographic and clinical characteristics, cardiovascular risk factors, comorbidities, tumor features, oncological treatment history, and cardiac management strategies.\n\nThe primary objective is to describe the clinical profile and management of patients with CHD in a real-world multicenter setting. Secondary objectives include identifying factors associated with advanced valvular dysfunction and evaluating eligibility and outcomes of transcatheter valve therapies. The registry is expected to improve risk stratification and support clinical decision-making in carcinoid heart disease.",[70,71,27,72],"Carcinoid Heart Disease","Neuroendocrine Tumors","Valvular Heart Disease Patients",[70,74,27,75,76,77,78,79],"Neuroendocrine Tumor","Valvular Heart Disease","Transcatheter Tricuspid Valve Intervention","Observational Study","Multicenter Registry","Right-Sided Heart Failure","NOT_YET_RECRUITING","2026-02-27",{"date":83,"type":48},"2026-03-04",{"date":85,"type":21},"2026-06-01",{"date":87,"type":21},"2027-06-01",{"name":89,"class":90},"National Institute of Cardiology, Warsaw, Poland","OTHER",1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":17,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":91},"100497389","fibrosis-in-chronic-and-delayed-myocardial-infarction-100497389","NCT05756608","Fibrosis in Chronic and Delayed Myocardial Infarction","FCDMI","Inclusion Criteria:\n\nCohort 1(Aortic stenosis):\n\n* Male or female above the age of 50 years old\n* Provision of informed consent prior to any study specific procedures\n* 25 patients with symptomatic severe aortic stenosis (peak velocity \\>4.0 m\u002Fs)\n* 25 patients with moderate aortic stenosis (peak velocity 3.0-4.0 m\u002Fs)\n* 10 patients with mild aortic stenosis (peak velocity 2.6-2.9 m\u002Fs)\n* 10 patients with aortic sclerosis (tri-leaflet thickened aortic valve with no obstruction of ventricular outflow)\n* 10 healthy volunteers (no other significant co-morbidities, as assessed by the study PI)\n\nCohort 2 (Chemotherapy-induced cardiotoxicity):\n\n* Male or female over the age of 35 years with evidence of cardiotoxicity on cardiac MRI (performed as part of the Cardiac care study), at least 1 year after anthracycline treatment.\n* 10 patients over the age of 35 years (male or females) without evidence of fibrosis on their 1-year scan after anthracycline treatment.\n* 10 healthy volunteers (\\>35 years of age) with no significant co-morbidities, as assessed by the study PI.\n* Provision of informed consent prior to any study specific procedures\n\nCohort 3 (Carcinoid syndrome):\n\n* 30 patients with carcinoid syndrome (with or without cardiac involvement), over the age of 35 years, diagnosed as per consensus guidelines\n* Provision of informed consent prior to any study specific procedures\n\nExclusion Criteria:\n\n* Inability or unwilling to give informed consent.\n* History of claustrophobia or feeling of inability to tolerate supine position for the MRI scans.\n* Impaired renal function with eGFR of \\\u003C30 mL\u002Fmin\u002F1.73m2.\n* Women who are pregnant or breastfeeding.\n* Contrast allergy\n* Contraindication to cardiac MRI (e.g. metallic implant or severe claustrophobia)\n* Recent myocardial infarction, other known causes of cardiomyopathy\u002Fcardiac fibrosis.",true,"40 Years","90 Years",{"count":103,"type":21},180,"In this study the investigators aim to examine the role that fibrosis plays in heart conditions such as aortic stenosis , chemotherapy-induced cardiotoxicity and carcinoid syndrome . Fibrosis is a common final result following any injury to the heart muscle and the investigators aim to identify this process early and in its active state. This will be examined by using a radiotracer 68Ga-FAPI or 18F-AlF-FAPI and PET-MRI or PET-CT.",[106,107,27],"Aortic Stenosis","Chemotherapy Induced Systolic Dysfunction","2026-01-08",{"date":110,"type":48},"2026-01-09",{"date":112,"type":48},"2022-11-10",{"date":114,"type":21},"2028-08-31",{"name":116,"class":90},"University of Edinburgh"]